Development of Delpazolid for the Treatment of Tuberculosis [PDF]
Applied Sciences (Switzerland), 2020 A novel oxazolidinone with cyclic amidrazone, delpazolid (LCB01-0371), was synthesized by LegoChem BioSciences, Inc. (Daejeon, Korea). Delpazolid can improve the minimum bactericidal concentration of Mycobacterium tuberculosis H37Rv and significantly ...
Jichan Jang, Young Lag Cho
exaly +12 more sources
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis [PDF]
Trials, 2023 Background Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a
A Dierig +24 more
doaj +19 more sources
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis. [PDF]
Antimicrobial Agents and Chemotherapy, 2022 Delpazolid, an oxazolidinone, has been studied in non-clinical studies of efficacy and toxicity and Phase 1 clinical studies. Delpazolid has in vitro activity against Gram-positive bacteria, including Mycobacterium tuberculosis .
Sang Haak Lee +2 more
exaly +8 more sources
Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial. [PDF]
Microbiology SpectrumMethicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a serious clinical challenge due to limited treatments and high mortality. We conducted both preclinical and clinical studies to assess the potential role of delpazolid in combination with ...
Hong Bin Kim, Seongman Bae, Eu Suk Kim
exaly +6 more sources
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? [PDF]
PharmaceuticsMultidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity.
Lina Davies Forsman, Jin-Gun Cho
exaly +6 more sources
Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China [PDF]
International Journal of Infectious Diseases, 2021 Background: The natural resistance of rapidly growing mycobacteria (RGM) to multiple antibiotics renders the treatment of the infections caused less successful.
Xia Yu, Xiaopan Gao, Hairong Huang
exaly +5 more sources
Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection [PDF]
Scientific Reports, 2023 The prevalence of Mycobacterium avium complex-pulmonary disease (MAC-PD) has become a growing concern worldwide, and current treatments involving macrolides (clarithromycin [CLR] or azithromycin), ethambutol, and rifampicin have limited success ...
Ju Mi Lee +5 more
doaj +3 more sources
In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China [PDF]
Infection and Drug Resistance, 2021 Xia Yu,* Fengmin Huo,* Fen Wang,* Shu’an Wen, Guanglu Jiang, Yi Xue, Lingling Dong, Liping Zhao, Rui Zhu, Hairong Huang National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Yu X +9 more
doaj +5 more sources
Comparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic. [PDF]
Translational and Clinical PharmacologyDelpazolid is an oxazolidinone-class antibiotic under development for treating diseases caused by antimicrobial-resistant gram-positive bacteria. This study compared the pharmacokinetics (PK) and safety of two formulations of delpazolid 400 mg with distinct excipient compositions: Batch No. 3183817R (test drug) and Batch No. 1650006 (reference drug). A
Young Lag Cho +2 more
exaly +4 more sources
Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China [PDF]
Frontiers in Medicine, 2022 ObjectiveTo investigate the in vitro activities of five oxazolidinones in parallel against the reference strains of different mycobacterial species and clinical isolates of Mycobacterium tuberculosis (Mtb), and shed light on the differences in the ...
Chenqian Wang +10 more
doaj +2 more sources